| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
(3-Hydroxyphenyl)boronic acid is a drug intermediate used for the synthesis of 17β-hydroxysteroid dehydrogenase type 1 inhibitors. 17β-HSD1 is an enzyme that converts estrone to the more potent estrogen estradiol, and its inhibition is a target for hormone-dependent cancers such as breast cancer. The compound also demonstrates significant potential in modulating steroid hormone metabolism.
|
|---|---|
| ln Vitro |
In vitro, (3-hydroxyphenyl)boronic acid is primarily used as a chemical reagent and synthetic intermediate. It is a key intermediate for developing inhibitors of 17β-hydroxysteroid dehydrogenase type 1. The compound has been shown to react with dopamine at physiological pH levels, forming a colorless product. It also has antiviral activities against human serum and inhibits the growth of multi-walled carbon nanotubes.
|
| ln Vivo |
In vivo data for (3-hydroxyphenyl)boronic acid as a therapeutic agent are limited. The compound is a synthetic intermediate used in the development of 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Its in vivo relevance is primarily indirect, through the biological activities of the final pharmaceutical compounds derived from its hydroxyphenyl scaffold. Specific in vivo efficacy and pharmacokinetic data for the parent compound are not well-documented.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, (3-hydroxyphenyl)boronic acid is used as a building block for the synthesis of 17β-hydroxysteroid dehydrogenase type 1 inhibitors. The final compounds are evaluated for enzyme inhibitory activity using standard assays. Recombinant 17β-HSD1 enzyme is incubated with the test compound and substrate (estrone), and enzyme activity is measured by detecting the formation of estradiol. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based experiments, (3-hydroxyphenyl)boronic acid is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using (3-hydroxyphenyl)boronic acid are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For 17β-HSD1 inhibitors and other hormone-targeting agents derived from this building block, efficacy studies would typically be performed in mouse xenograft models of hormone-dependent cancers. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of tumor volume over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (3-hydroxyphenyl)boronic acid as a standalone compound are not characterized in the literature. The compound has a molecular weight of 137.93 g/mol, which is favorable for oral bioavailability. The hydroxyl group may influence water solubility and metabolic conjugation (e.g., glucuronidation, sulfation). As a boronic acid, it may be subject to metabolic oxidation. Empirical pharmacokinetic data are not available.
|
| Toxicity/Toxicokinetics |
(3-Hydroxyphenyl)boronic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a boronic acid derivative, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| References | |
| Additional Infomation |
(3-Hydroxyphenyl)boronic acid (3-Hydroxybenzeneboronic acid, CAS 87199-18-6) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a key intermediate for the synthesis of 17β-hydroxysteroid dehydrogenase type 1 inhibitors and for modulating steroid hormone metabolism. No clinical trials or approved therapeutic indications exist for this compound.
|
| Molecular Formula |
C6H7BO3
|
|---|---|
| Molecular Weight |
137.928982019424
|
| Exact Mass |
138.048
|
| CAS # |
87199-18-6
|
| PubChem CID |
2734359
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
370.0±44.0 °C at 760 mmHg
|
| Melting Point |
210-213 °C (dec.)(lit.)
|
| Flash Point |
177.6±28.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
0.85
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
107
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(C1=CC(=CC=C1)O)(O)O
|
| InChi Key |
WFWQWTPAPNEOFE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7BO3/c8-6-3-1-2-5(4-6)7(9)10/h1-4,8-10H
|
| Chemical Name |
(3-hydroxyphenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~725.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (18.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2501 mL | 36.2503 mL | 72.5005 mL | |
| 5 mM | 1.4500 mL | 7.2501 mL | 14.5001 mL | |
| 10 mM | 0.7250 mL | 3.6250 mL | 7.2501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
